Heterogeneity of second-line treatment for patients with multiple myeloma in the Connect ® MM Registry (2010–2016)

Connect ® MM is a large prospective observational US-based disease registry that was used to evaluate second-line treatment patterns in patients with relapsed or refractory multiple myeloma during a 5-year period, from 2010 to 2016. Treatment uptake was found to coincide with clinical milestones (i.e., reg ulatory approvals, clinical study results), with growing preference for newer agents and triplet combinations over time.

Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2018 Category: Hematology Authors: Sundar Jagannath, Rafat Abonour, Brian G.M. Durie, Cristina Gasparetto, James W. Hardin, Mohit Narang, Howard R. Terebelo, Kathleen Toomey, Lynne Wagner, Shankar Srinivasan, Amani Kitali, Lihua Yue, E. Dawn Flick, Amit Agarwal, Robert M. Rifkin Tags: Original Study Source Type: research